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Background
Whereas 40 % to 70 % of papillary thyroid carcinomas
(PTCs) are characterized by a BRAF mutation (BRAFmut),
unified biomarkers for the genetically heterogeneous
group of BRAF wild type (BRAFwt) PTCs are not estab-
lished yet [1,2]. Using state-of-the-art technology we com-
pared RNA expression profiles between conventional
BRAFwt and BRAFmut PTCs.
Materials and methods
Affymetrix HuGene 1.0 ST microarrays were used to
generate whole transcript expression profiles in 11
BRAFwt and 14 BRAFmut PTCs. A p-value with a false
discovery rate (FDR) ≤ 0.05 and a fold change > 2 were
used as a threshold of significance for differential expres-
sion. Spearman’s correlation as a similarity matrix was
utilized for unsupervised two dimensional hierarchical
clustering. The BRAF mutational status was surveyed by
direct sequencing the hotspot region of BRAF exon 15.
Results
Hundred eighty transcripts from annotated genes were
significantly differentially expressed between BRAFwt and
BRAFmut PTCs and unsupervised cluster analysis was
able to separate both groups. The most significantly
upregulated genes in BRAFmut compared to BRAFwt
PTCs include transmembrane 7 superfamily member 4
(TM7SF4, located on 8q23), glutaminase 2 (GLS2;
12q13), ladinin 1 (LAD1; 1q25.1-q32.3), TBC1 domain
family, member 2 (TBC1D2; 9q22.33), chromosome
19 open reading frame 33 (C19orf33; 19q13.2), keratin
19 (KRT19; 17q21.2), and poliovirus receptor-related
4 (PVRL4; 1q22-q23.2). The most downregulated genes
in BRAFmut PTCs include inositol 1,4,5-triphosphate
receptor, type 1 (ITPR1; 3p26-p25), leucine rich repeat
and Ig domain containing 2 (LINGO2; 9p21.2-p21.1),
solute carrier family 26, member 4 (SLC26A4: 7q31),
deiodinase, iodothyronine, type I (DIO1; 1p33-p32), and
hepatic leukemia factor (HLF; 17q22). Among differen-
tially expressed microRNAs, mir492 was highly upregu-
lated in BRAFmut PTCs.
Conclusions
This study provides a detailed overview of differentially
expressed genes between BRAFwt vs. BRAFmut conven-
tional PTCs using whole transcript, high-density microar-
rays. Valuable candidate genes shall be assessed further to
identify molecular pathways and molecular biomarkers
which distinguish BRAFwt from BRAFmut PTCs.
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